Clinical Trial Update: Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study of pemigatinib for advanced/metastatic or surgically unresectable cholangiocarcinoma, including FGFR2 rearrangements, s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED